886499-04-3

Usage

Uses

Used in Pharmaceutical Industry:
3-Fluoro-4-(trifluoromethoxy)benzyl bromide is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to act as a strong electrophile, facilitating reactions with a variety of nucleophiles. This property is essential in the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Fluoro-4-(trifluoromethoxy)benzyl bromide is utilized as a precursor in the production of agrochemicals, contributing to the creation of compounds with pesticidal or herbicidal activities, thereby enhancing crop protection and yield.
Used in Organic Synthesis:
3-Fluoro-4-(trifluoromethoxy)benzyl bromide is employed as a versatile building block in organic synthesis for the preparation of biologically active molecules. Its reactivity allows for the formation of diverse chemical structures, which can be further modified for specific applications in research and development.
Given the high reactivity of 3-Fluoro-4-(trifluoromethoxy)benzyl bromide, it is imperative to handle 3-FLUORO-4-(TRIFLUOROMETHOXY)BENZYL BROMIDE with care to ensure safety in laboratory and industrial settings.

Upstream product

• 473917-15-6 3-fluoro-4-(trifluoromethoxy)benzaldehyde 
• 886498-99-3 (3-fluoro-4-(trifluoromethoxy)phenyl)methanol 

Relevant academic research and scientific papers

TRIAZOLE COMPOUNDS AS T-TYPE CALCIUM CHANNEL BLOCKERS

The invention relates to compounds of formula (I) wherein X, Y, R1, R2, (R4)n, and (R5)m are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium T-channel blockers.

Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((S)-2-nitro-6,7-dihydro-5 H -imidazo[2,1- b ][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824)

The (S)-2-nitro-6-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2, 1-b][1,3]oxazine named PA-824 (1) has demonstrated antitubercular activity in vitro and in animal models and is currently in clinical trials. We synthesized derivatives at three positions of the 4-(trifluoromethoxy)benzylamino tail, and these were tested for whole-cell activity against both replicating and nonreplicating Mycobacterium tuberculosis (Mtb). In addition, we determined their kinetic parameters as substrates of the deazaflavin-dependent nitroreductase (Ddn) from Mtb that reductively activates these pro-drugs. These studies yielded multiple compounds with 40 nM aerobic whole cell activity and 1.6 μM anaerobic whole cell activity: 10-fold improvements over both characteristics from the parent molecule. Some of these compounds exhibited enhanced solubility with acceptable stability to microsomal and in vivo metabolism. Analysis of the conformational preferences of these analogues using quantum chemistry suggests a preference for a pseudoequatorial orientation of the linker and lipophilic tail.